GPR35 and metabolic disease: Abnormalities in the coding and intergenic regions of GPR35 have been reported to be associated with metabolic diseases such as type 2 diabetes, and activation of GPR35 has been shown to prevent lipid accumulation by increasing energy expenditure in adipose tissue (14–17).